BaicalinCAS# 21967-41-9 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 21967-41-9 | SDF | Download SDF |
PubChem ID | 64982 | Appearance | Ochre or yellowish powder |
Formula | C21H18O11 | M.Wt | 446.37 |
Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
Synonyms | Baicalein 7-O-β-D-glucuronide | ||
Solubility | DMSO : ≥ 100 mg/mL (224.03 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | (2S,3S,4S,5R,6S)-6-(5,6-dihydroxy-4-oxo-2-phenylchromen-7-yl)oxy-3,4,5-trihydroxyoxane-2-carboxylic acid | ||
SMILES | C1=CC=C(C=C1)C2=CC(=O)C3=C(C(=C(C=C3O2)OC4C(C(C(C(O4)C(=O)O)O)O)O)O)O | ||
Standard InChIKey | IKIIZLYTISPENI-ZFORQUDYSA-N | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Baicalin has antioxidant, anti-inflammatory, anti-apoptotic, and neuroprotection actions, it is a known prolyl endopeptidase inhibitor, affects the GABA receptors, and reduces the expression of NF-κB. Baicalin may have significant therapeutic benefits against diabetic complications and atherosclerosis. |
Targets | Caspase | NF-kB | TNF-α | IL Receptor | ROS |
In vitro | Baicalin induces apoptosis via mitochondrial pathway as prooxidant.[Pubmed: 11841838]Mol Immunol. 2002 Feb;38(10):781-91.Baicalin is a flavonoid and a major component of a herbal medicine, Sho-saiko-to, which is commonly used for treatment of chronic hepatitis in Japan and China. Flavonoids including Baicalin have been reported to not only function as anti-oxidants but also cause cytotoxic effect.
|
In vivo | Baicalin, baicalein and wogonin inhibits high glucose-induced vascular inflammation in vitro and in vivo.[Pubmed: 25739393]BMB Rep. 2015 Mar 5. pii: 3111.Vascular inflammatory process has been suggested to play a key role in initiation and progression of atherosclerosis, a major complication of diabetes mellitus.
Baicalin attenuates global cerebral ischemia/reperfusion injury in gerbils via anti-oxidative and anti-apoptotic pathways.[Pubmed: 21600966 ]Brain Res Bull. 2011 Jul 15;85(6):396-402.Baicalin is an important medicinal herb purified from the dry roots of Scutellaria baicalensis Georgi.
|
Cell Research | Baicalin Inhibits Lipopolysaccharide-Induced Inflammation Through Signaling NF-κB Pathway in HBE16 Airway Epithelial Cells.[Pubmed: 25630720]Inflammation. 2015 Jan 30.Baicalin, a flavonoid monomer derived from Scutellaria baicalensis called Huangqin in mandarin, is the main active ingredient contributing to S. baicalensis' efficacy. It is known in China that Baicalin has potential therapeutic effects on inflammatory diseases. However, its anti-inflammatory mechanism has still not been fully interpreted.
|
Baicalin Dilution Calculator
Baicalin Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.2403 mL | 11.2015 mL | 22.4029 mL | 44.8059 mL | 56.0073 mL |
5 mM | 0.4481 mL | 2.2403 mL | 4.4806 mL | 8.9612 mL | 11.2015 mL |
10 mM | 0.224 mL | 1.1201 mL | 2.2403 mL | 4.4806 mL | 5.6007 mL |
50 mM | 0.0448 mL | 0.224 mL | 0.4481 mL | 0.8961 mL | 1.1201 mL |
100 mM | 0.0224 mL | 0.112 mL | 0.224 mL | 0.4481 mL | 0.5601 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Baicalin is a flavonoid glycoside isolated from Scutellaria baicalensis. Baicalin reduces the expression of NF-κB.
In Vitro:Baicalin protects against ischemia-reperfusion injury (IRI) by altering the production of various mediators, including reactive oxygen species (ROS), Toll-like receptor (TLR)2 and TLR4, NF-κB, Bax, and Bcl-2. Baicalin treatment inhibits the increased expression of the proinflammatory cytokines TLR2/4, MyD88, p-NF-κB, and p- IκB, as well as increase the expression of IκB protein, an NF-κB inhibitor, with the degree of inhibition positively related to the dosage of Baicalin[1]. Cell viability is determined by MTT assay. Compared with control cells, cell viability is significantly decreased in SH-SY5Y cells treated with thrombin. Pre-treatment with Baicalin (5, 10, 20 μM) increases cell viability in a dose-dependent manner compared with cells treated thrombin alone[2].
In Vivo:Baicalin pretreatment dose-dependently protects against a loss of renal function, with the two higher doses (10 and 100 mg/kg) significantly decreasing Scr and blood urea nitrogen (BUN) concentrations. Tissue injury, as assessed using a 0-3 point scoring system, is lower for the Baicalin treated groups than for the ischemia-reperfusion (IR)+saline group. Compared with the sham group, malondialdehyde (MDA) content is only slightly up-regulated and the SOD activity is only slightly down-regulated in rats treated with 10 and 100 mg/kg Baicalin, indicating that Baicalin abrogates the increase in oxidative stress following reperfusion[1].
References:
[1]. Lin M, et al. The protective effect of Baicalin against renal ischemia-reperfusion injury through inhibition of inflammation and apoptosis. BMC Complement Altern Med. 2014 Jan 13;14:19.
[2]. Ju XN, et al. Baicalin protects against thrombin induced cell injury in SH-SY5Y cells. Int J Clin Exp Pathol. 2015 Nov 1;8(11):14021-7.
- Griffipavixanthone
Catalog No.:BCN4939
CAS No.:219649-95-3
- (R)-Coclaurine
Catalog No.:BCN8348
CAS No.:2196-60-3
- beta-Hydroxypropiovanillone
Catalog No.:BCN4938
CAS No.:2196-18-1
- 4',7-Dihydroxyflavone
Catalog No.:BCN3758
CAS No.:2196-14-7
- PD 173074
Catalog No.:BCC3662
CAS No.:219580-11-7
- Trans-Pinosylvin dimethyl ether
Catalog No.:BCN3495
CAS No.:21956-56-9
- Littorine
Catalog No.:BCN1917
CAS No.:21956-47-8
- Boc-Cys(Trt)-OH
Catalog No.:BCC3380
CAS No.:21947-98-8
- trans-Cinnamic anhydride
Catalog No.:BCN7914
CAS No.:21947-71-7
- Boc-Nle-OH.DCHA
Catalog No.:BCC3297
CAS No.:21947-32-0
- H-ß-HoIle-OH.HCl
Catalog No.:BCC3235
CAS No.:219310-10-8
- 2-Hydroxy-3,4,5,6-tetramethoxychalcone
Catalog No.:BCN1489
CAS No.:219298-74-5
- 14-Deoxy-12-hydroxyandrographolide
Catalog No.:BCN4673
CAS No.:219721-33-2
- Taxezopidine L
Catalog No.:BCN6946
CAS No.:219749-76-5
- ANA 12
Catalog No.:BCC6287
CAS No.:219766-25-3
- Bombiprenone
Catalog No.:BCN4940
CAS No.:21978-49-4
- BTB06584
Catalog No.:BCC5106
CAS No.:219793-45-0
- Consiculine
Catalog No.:BCN1903
CAS No.:219829-73-9
- Merresectine B
Catalog No.:BCN1918
CAS No.:219829-75-1
- Escitalopram Oxalate
Catalog No.:BCC5040
CAS No.:219861-08-2
- 2,2',3'-Trihydroxy-4,6-dimethoxybenzophenone
Catalog No.:BCN1488
CAS No.:219861-73-1
- MPEP Hydrochloride
Catalog No.:BCC1777
CAS No.:219911-35-0
- 5,8,9,14-Tetraacetoxy-3-benzoyloxy-10,15-dihydroxypepluane
Catalog No.:BCN7657
CAS No.:219916-77-5
- 3-Methyl-1-(2-piperidinophenyl)butylamine N-acetylglutamate salt
Catalog No.:BCC8635
CAS No.:219921-94-5
Baicalin induces apoptosis via mitochondrial pathway as prooxidant.[Pubmed:11841838]
Mol Immunol. 2002 Feb;38(10):781-91.
Baicalin is a flavonoid and a major component of a herbal medicine, Sho-saiko-to, which is commonly used for treatment of chronic hepatitis in Japan and China. Flavonoids including Baicalin have been reported to not only function as anti-oxidants but also cause cytotoxic effect. We investigated the mechanism of Baicalin-induced cytotoxicity in leukemia-derived T cell line, Jurkat cells. When cells were cultured with 50-200 microg/ml Baicalin for 6h, caspase-3 was activated and then cells fell into apoptosis. Induction of apoptosis by Baicalin was accompanied with the marginal generation of intracellular reactive oxygen species (ROS), the increase of the cytosolic fractions of cytochrome c, and the disruption of mitochondrial transmembrane potential (DeltaPsi(m)) prior to the activation of caspase-3. The pre-culture with 5 mM of buthionine sulfoximine (BSO), an inhibitor of glutathione (GSH) synthesis, facilitated Baicalin-induced disruption of DeltaPsi(m) and induction of apoptosis. The pre-culture with N-benzyloxycarbonyl-valyl-alanyl-aspartyl fluoromethylketone (Z-VAD-fmk), a pan-caspase inhibitor, partially suppressed the induction of apoptosis. On the other hand, Baicalin showed little toxic effect on peripheral blood mononuclear cells (PBMCs) from healthy volunteers. These results indicate that Baicalin acts as a prooxidant and induces caspase-3 activation and apoptosis via mitochondrial pathway.
Baicalin, baicalein and wogonin inhibits high glucose-induced vascular inflammation in vitro and in vivo.[Pubmed:25739393]
BMB Rep. 2015 Sep;48(9):519-24.
Vascular inflammatory process has been suggested to play a key role in initiation and progression of atherosclerosis, a major complication of diabetes mellitus. Thus, in this study, we attempted to determine whether three structurally related polyphenols found in the Chinese herb Huang Qui, namely Baicalin, baicalein, and wogonin, can suppress vascular inflammatory processes induced by high glucose (HG) in human umbilical vein endothelial cells (HUVECs) and mice. Data showed that HG induced markedly increased vascular permeability, monocyte adhesion, expressions of cell adhesion molecules (CAMs), formation of reactive oxygen species (ROS) and activation of nuclear factor (NF)-kappaB. Remarkably, all of the above mentioned vascular inflammatory effects of HG were attenuated by pretreatment with Baicalin, baicalein, and wogonin. Vascular inflammatory responses induced by HG are critical events underlying development of various diabetic complications, therefore, our results suggest that Baicalin, baicalein, and wogonin may have significant therapeutic benefits against diabetic complications and atherosclerosis.
Baicalin attenuates global cerebral ischemia/reperfusion injury in gerbils via anti-oxidative and anti-apoptotic pathways.[Pubmed:21600966]
Brain Res Bull. 2011 Jul 15;85(6):396-402.
Baicalin is an important medicinal herb purified from the dry roots of Scutellaria baicalensis Georgi. The present study was undertaken to evaluate the neuroprotective effects of Baicalin in gerbils subjected to transient global cerebral ischemic-reperfusion injury. Baicalin at doses of 50, 100 and 200mg/kg was intraperitoneally injected into the gerbils immediately after cerebral ischemia. Seven days after reperfusion, hematoxylin and eosin (HE) staining was performed to analyze hippocampal CA1 pyramidal damage histopathologically. In addition, in order to understand the potential protective mechanism of Baicalin, we examined anti-oxidative enzymes, such superoxide dismutase (SOD), glutathione peroxidase (GSH-PX), non-enzymatic scavenger glutathione (GSH) and measured the content of malondialdehyde (MDA) in hippocampus. The mRNA and protein expressions of BDNF were determined in ischemic hippocampus by real-time RT-PCR and Western blot, respectively. Evidence for neuronal apoptosis was detected by real-time RT-PCR, Western blot and caspase-3 activity measurement. Histopathological examination showed that the administration of Baicalin by the dose of 100 and 200mg/kg significantly attenuated ischemia-induced neuronal cell damage. Reduced level of MDA, obviously elevated activities of SOD and GSH as well as GSH-PX were also found in Baicalin-treated groups. Further investigation demonstrated that treatment with Baicalin remarkably promoted the expression of BDNF and inhibited the expression of caspase-3 at mRNA and protein levels by real-time RT-PCR and Western blot, respectively. Besides, caspase-3 activity assay also elucidated that the administration of Baicalin could significantly suppress caspase-3 in ischemic gerbils hippocampus. Theses findings suggest that Baicalin's neuroprotection appears to be associated with its anti-oxidative and anti-apoptotic properties in global cerebral ischemia in the gerbils.
Baicalin Inhibits Lipopolysaccharide-Induced Inflammation Through Signaling NF-kappaB Pathway in HBE16 Airway Epithelial Cells.[Pubmed:25630720]
Inflammation. 2015 Aug;38(4):1493-501.
Baicalin, a flavonoid monomer derived from Scutellaria baicalensis called Huangqin in mandarin, is the main active ingredient contributing to S. baicalensis' efficacy. It is known in China that Baicalin has potential therapeutic effects on inflammatory diseases. However, its anti-inflammatory mechanism has still not been fully interpreted. We aim to investigate the anti-inflammatory effect of Baicalin on lipopolysaccharide (LPS)-induced inflammation in HBE16 airway epithelial cells and also to explore the underlying signaling mechanisms. The anti-inflammatory action of Baicalin was evaluated in human airway epithelial cells HBE16 treated with LPS. Airway epithelial cells HBE16 were pretreated with a range of concentrations of Baicalin for 30 min and then stimulated with 10 mug/ml LPS. The secretions of interleukin-6 (IL-6), interleukin-8 (IL-8), and tumor necrosis factor-alpha (TNF-alpha) in cell culture supernatants were quantified by enzyme-linked immunosorbent assay (ELISA). The messenger RNA (mRNA) expressions of IL-6, IL-8, and TNF-alpha were tested by quantitative real-time polymerase chain reaction (real-time RT-PCR). Furthermore, Western blotting was used to determine whether the signaling pathway NF-kappaB was involved in the anti-inflammatory action of Baicalin. The inflammatory cell model was successfully built with 10 mug/ml LPS for 24 h in our in vitro experiments. Both the secretions and the mRNA expressions of IL-6, IL-8, and TNF-alpha were significantly inhibited by Baicalin. Moreover, the expression levels of phospho-IKKalpha/beta and phospho-NF-kappaB p65 were downregulated, and the phospho-IkappaB-alpha level was upregulated by Baicalin. These findings suggest that the anti-inflammatory properties of Baicalin may be resulted from the inhibition of IL-6, IL-8, and TNF-alpha expression via preventing signaling NF-kappaB pathway in HBE16 airway epithelial cells. In addition, this study provides evidence to understand the therapeutic effects of Baicalin on inflammatory diseases in clinical practice.